Navigation Links
Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
Date:6/2/2009

Promising Preliminary Results on Radiation Sensitization from Phase II Trial May Serve as Additional Registration Direction for OPAXIO

ORLANDO, Fla., June 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that, in a study released from Brown University at the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting, patients with cancer of the lower esophagus had evidence of a high pathological complete response ("CR") rate when given OPAXIO, a biologically enhanced paclitaxel, in addition to cisplatin and full-course radiotherapy.

Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, a regimen associated with a 15% to 17% pathologic CR rate (complete elimination of the cancer in the surgical specimen) and a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4 -fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int'l J. Radiat. Oncol. Biol. Phys. 55(3), 707-12 (2003)).

The Brown University Oncology Group lead by Dr. Howard Safran published preliminary data on their phase II trial in the ASCO proceedings. In this study, which follows their earlier report of a phase IB trial (Dipetri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
4. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
5. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
6. Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
7. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
8. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
9. Winning the War on Cancer: The Critical Role of Radiation Oncology
10. Breast MRI Scan Could Determine Need for Radiation Therapy
11. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... announced that Mr. Ofir Paz, InspireMD,s co-founder and chief ... will participate in the Benchmark Company, LLC One-on-One Investor ... Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. The conference ...
... Axcan Intermediate Holdings Inc. announces that it ... the recently completed combination of two specialty pharma companies ... also has a new corporate logo and website (please ... "Our new name, Aptalis, is intended to capture the ...
Cached Medicine Technology:InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 2InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 3The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 2The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 3
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:11/22/2014)... 22, 2014 The topic of B&D ... block retaining walls. The article states that, “While they give ... necessary steps that go into creating this powerful look.” , ... retaining wall is choosing which kind of block matches your ... B&D Rockeries says, “The two main options are concrete and ...
(Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Those air-blown ... germs than conventional paper towels, a new study suggests. ... on the hands of volunteers in order to simulate ... dryers, high-powered "jet-air" dryers or paper towels to dry ... and found higher amounts of germs around both types ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... WEDNESDAY, Aug. 25 (HealthDay News) -- Even prior to ... in four American parents with health insurance reported that their ... medical care their children needed. Parents of kids with ... to say their insurance coverage did not meet their needs, ...
... and promise of using thermal ablation to target and ... of Vascular and Interventional Radiology ,s August supplement, "Thermal ... Goals and Future Technology." "The Journal ... on the development of multiple medical techniques and devices ...
... 11 states will receive more than $6 million in ... on substance abuse and associated problems among U.S. military ... Drug Abuse (NIDA), part of the National Institutes of ... to award grants that will examine substance abuse related ...
... treat metastatic melanoma tumors with a specific genetic signature was successful ... clinical trial. Results of the trial of PLX4032, an inhibitor ... half of all melanomas, appear in the August 26 New ... and is one of the top causes of cancer death in ...
... 25 Vitamin D may be an effective therapy to ... can cause severe complications for patients with cystic fibrosis and ... UPMC, the University of Pittsburgh School of Medicine and Louisiana ... by Jay Kolls, M.D., Ph.D., a lung disease researcher at ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Aug. ... to an inheritable eye disease that affects 5 percent of ... for transplants of the cornea. The genetic disorder, ... the cornea -- the thin, clear membrane that covers the ...
Cached Medicine News:Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 2Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 3Health News:Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 3Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 2Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 3Health News:Vitamin D may treat and prevent allergic reaction to mold in cystic fibrosis patients 2Health News:Study Links Gene to Serious Eye Disease 2
Inquire...
Inquire...
One Piece: Premier Pouches - Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
Inquire...
Medicine Products: